Clinical Trial Update: Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating an anti-PD-1 inhibitor in combination with albumin-bound paclitaxel for recurrent cervical cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Anti-PD-1 inhibitor

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent Cervical Cancer | Phase 2 | Status: COMPLETED